Evidence map›Paper›PMID 41864908›Full record

ReviewJournal of nanobiotechnology2026

Biogenesis, preparation, characterization, therapeutic mechanisms and safety evaluation of plant-derived exosome-like nanovesicles in the treatment of ulcerative colitis.

Cailan Li, Luyou Zhao, Xuefei Wang, Jingjing Wu, Haohui Chen, Qiang Lu

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cailan LiDepartment of Pharmacology, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China. licailan@zmu.edu.cn.
Luyou ZhaoDepartment of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China.
Xuefei WangDepartment of Pharmacology, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China.
Jingjing WuDepartment of Pharmacology, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China.
Haohui ChenDepartment of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China.
Qiang LuDepartment of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai, 519041, PR China. luqiang@zmu.edu.cn.

Funding

National Natural Science Foundation of China 82304828National Natural Science Foundation of China 82360809
6 · The paper itself

Abstract

Ulcerative colitis remains a challenging clinical condition due to its complex etiology and the limitations of current therapies. Plant-derived exosome-like nanovesicles (PDELNs) represent a new class of natural nanotherapeutics with significant potential for ulcerative colitis treatment. These nanoparticles exhibit high biocompatibility, the ability to cross biological barriers, and carry a rich cargo of bioactive molecules. This review synthesizes progress in PDELN research over the past decade, focusing on established preparation methods and their multi-targeted therapeutic mechanisms. The current isolation methods of the anti-colitis PDELNs are mainly various types of centrifugation, including ultracentrifugation, differential centrifugation, density gradient centrifugation and their combination. Therapeutically, PDELNs alleviate colitis through potent anti-inflammatory effects, gut microbiota remodeling, and immune response regulation. These effects are attributed to key bioactive components such as plant microRNAs, metabolites, and lipids. Notably, PDELNs demonstrate an excellent safety profile without reported toxicity. Their natural origin, multi-targeted mechanisms, and favorable biosafety profile make PDELNs a promising next-generation therapeutic candidate against colitis, effectively bridging traditional phytotherapy and modern nanomedicine.

Indexed as

Colitis, UlcerativeExosomesNanoparticlesPlantsAnimalsAnti-Inflammatory AgentsHumansNanomedicineAnti-Inflammatory AgentsActive componentsColitisMolecular mechanismPlant-derived exosome-like nanovesiclesSafetyTherapeutic effect

Identifiers

PMID41864908
PMCPMC13130446

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.